Late Phase Research in the Life Sciences segment is undergoing a rapid transformation due to the digitalisation of healthcare and the greater availability of, and access to, Real World Data (RWD). This transformation is arriving not a moment too soon, given the changes anticipated from the Twenty-first Century Cures Act, EMA’s Adaptive Pathways approach, and the increased demand for Real World Evidence (RWE) generated from these RWD. In addition to supporting regulatory decisions, RWE is playing an ever expanding role in developing the product value propositions that are driving reimbursement decisions globally.
Immune repertoire profiling provides better outcomes for immuno-oncology development programs .
This whitepaper offers a résumé of regulations under which eConsent solutions and vendors may fall and, more importantly, discusses the practical implications of those regulations for vendors and those responsible for designing and executing research plans.
Current MRD detection landscape, key considerations for each approach, and current advancements that will contribute to further improvements in MRD detection.
This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola.
Discover how a comprehensive personalized genomics strategy can help you identify the patients who would most likely benefit from a treatment and suffer the least side effects, ensuring the right drug is used in the right patient at the right time.
Learn what bioinformatics offers to precision medicine and immuno-oncology.
Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
|
|
|
|
|
|
|
|
|